Tag Archives: NICE

UK: Further Steps Toward Value-Based Assessment

By Leela Barham. The National Institute for Health and Care Excellence (NICE) has finally published the formal consultation on value-based assessment (VBA). VBA is the new VBP, incorporating a wider assessment of value and no longer clearly linking to price in quite the way that some speculated all the way back in 2010 when VBP […]
Posted in Europe, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , , , , , | Leave a comment

UK Drug Pricing: An ICER of Zero?

by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
Posted in Europe, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , | Leave a comment

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Posted in Europe, Events, pricing | Also tagged , , , , | Leave a comment

NICE's Tarceva Decision "Perverse", Says Roche

The UK National Institute for Health and Care Excellence’s (NICE) decision that relapsed non-small cell lung cancer patients should no longer have access to Roche’s cancer pill Tarceva (erlotinib) is a setback for lung cancer care in England and Wales, where “over 1,000 patients a year will be left without an active treatment option after […]
Posted in pricing, Regulatory | Also tagged , , , , | Leave a comment

Who's Watching the Drug Watchdogs?

It is nowadays fashionable to question everyone in authority, and there is no shortage of self-appointed watchdogs who aim to make sure that things that happen are happening as they should. The drug industry and drug regulatory authorities have been among the most conspicuous targets of this intense monitoring, on everything from questionable payments to […]
Posted in Europe, Global, Guest Blog, Op-Ed, Regulatory | Also tagged , , , , | 1 Comment
  • Categories

  • Meta